Program overview
Context
Indication: Multiple Myeloma
Mechanism: Unknown
Modality: Unknown
Sponsor: Hoffmann-La Roche
Cevostamab is flagged as operational burden signal because public records show operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Indication: Multiple Myeloma
Mechanism: Unknown
Modality: Unknown
Sponsor: Hoffmann-La Roche
Registry: 0/5
Timeline: 1/5
Recruitment burden: 3/5
Results availability: 0/5
Program risk: 2/5
https://clinicaltrials.gov/study/NCT05535244
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT05535244 | Low Signal (ACTIVE_NOT_RECRUITING) | long_recruitment_duration_signal | Low Signal | rare_population_signal | strict_eligibility_signal | complex_intervention_signal |